Permanent hearing loss affects more than 5% of the world's population, yet there are no
nondevice therapies that can protect or restore hearing. Delivery of therapeutics to the …

Nanoscale drug delivery systems using liposomes and nanoparticles are emerging
technologies for the rational delivery of chemotherapeutic drugs in the treatment of cancer …

Administration of substances to laboratory animals requires careful consideration and
planning to optimize delivery of the agent to the animal while minimizing potential adverse …

Offering the latest information in magnetic nanoparticle (MNP) research, Magnetic
Nanoparticles: From Fabrication to Clinical Applications provides a comprehensive review …

Local drug delivery to the ear has gained wide clinical acceptance, with the choice of drug
and application protocol in humans largely empirically-derived. Here, we review the …

As more and more substances have been shown in preclinical studies to be capable of
preventing damage to the inner ear from exposure to noise, ototoxic drugs, ischemia …

Impairments of vision and hearing are highly prevalent conditions limiting the quality of life
and presenting a major socioeconomic burden. For a long time, retinal and cochlear …

Inner ear diseases are not adequately treated by systemic drug administration mainly
because of the blood–perilymph barrier that reduces exchanges between plasma and inner …

Most therapies for treating sensorineural hearing loss are challenged by the delivery across
multiple tissue barriers to the hard-to-access anatomical location of the inner ear. In this …

An estimated 466 million people suffer from hearing loss worldwide. Sensorineural hearing
loss is characterized by degeneration of key structures of the sensory pathway in the …